OUR TEAM
steers us towards breakthrough therapies
OUR
Management Team
Adam Rosenthal, PhD
CEO, Founder, and Board Chair
Sandip Panicker, PhD
CSO
Scott Robertson, MBA
CBO and CFO
Monica Kamio
SVP, Head of HR
Adam Rosenthal PhD
CEO, Founder, and Board Chair
Adam founded Star Therapeutics in 2018 and has served as Chief Executive Officer since its inception. He brings previous operating experience across multiple biotech companies, and broad expertise in company building, fundraising, business development, and strategic planning.
Prior to founding Star, Adam was a Co-Founder and CEO of Electra Therapeutics, where he currently serves as a Board Director. He was also Chief Business Officer at True North Therapeutics, where he raised more than $140M in private financing and contributed to the company’s acquisition by Bioverativ for $825M. His experience also includes serving as Vice President, Head of Corporate Development at iPierian, which was acquired by BMS for $725M, and being a Project Leader at the Boston Consulting Group.
Adam earned BS degrees in Electrical Engineering and Brain and Cognitive Science, and an MEng degree in Electrical Engineering and Computer Science, all at Massachusetts Institute of Technology, as well as a PhD in Biomedical Engineering at the Massachusetts Institute of Technology and Harvard.
Sandip Panicker PhD
CSO
Sandip is the Chief Scientific Officer and Co-Founder of Star Therapeutics. He is focused on identifying common physiological processes in different diseases to recognize pathways that can be targeted in drug development. He partners with the team of scientists at Star, as well as academic and clinical collaborators, to explore and develop novel ideas and bring them to fruition.
Sandip started his drug-hunting experience as a scientist at Roche in biochemical pharmacology, and then as a member of the inflammation/autoimmune group, where he began his foray into immunology. He then joined True North Therapeutics as Head of Discovery Biology and led a program targeting complement C1s that resulted in the discovery of ENJAYMO, a molecule that earned FDA Breakthrough Therapy Designation and approval for a rare condition called cold agglutinin disease.
Sandip earned his BA at the University of California, Berkeley, and his PhD at the University of California, San Diego.
Scott Robertson MBA
CBO and CFO
Monica Kamio
SVP, Head of Human Resources
Monica is the SVP, Head of Human Resources, at Star Therapeutics. She oversees all aspects of HR strategy and operations, including recruitment, talent management, compensation, benefits, learning and development, and culture. She is dedicated to fostering a positive, high-performance environment that contributes to organizational growth and employee engagement.
With over 20 years of experience in human resources across the life sciences and financial services industries, Monica held pivotal roles that have shaped company cultures and enhanced operational efficiency. Prior to Star, Monica served as Senior HR Consultant at Christine Mathews Consulting, a One Digital company, working with life science start-up organizations to design and enhance HR infrastructures, focusing on operational efficiency, organizational development, talent management, and culture initiatives. Prior to CMC, she served as Vice President of Human Resources at Arch Capital Services Inc., where she successfully unified HR practices across international divisions and implemented impactful talent management strategies. In this role, she collaborated with senior leadership to develop comprehensive HR frameworks that aligned with business needs, driving initiatives in talent management, DE&I, succession planning, and employee engagement.
Monica holds a bachelor’s degree in communications from the University of San Francisco and SPHR certification from HRCI.
OUR
Board of Directors
Adam Rosenthal, PhD
CEO, Founder, and Board Chair
Amrit Nagpal
Director
Carl Gordon, PhD, CFA
Director
Matthew Fust, MBA
Director
Nancy Stagliano, PhD
Director
Matthew Hammond, PHD, MBA
Board Observer
Vish Sridharan, MD
Board Observer
NANCY STAGLIANO PHD
Director
Nancy is CEO and Chair of the Board of Neuron23, Inc., a South San Francisco–based precision neurology and immunology therapeutics company. An experienced CEO, Nancy has led True North Therapeutics (acquired by Bioverativ in 2017), iPierian (acquired by BMS in 2014), and CytomX Therapeutics (CTMX). With more than 20 years of experience in the biotechnology industry, Nancy’s career path has always stayed close to the science, beginning with 7+ years at Millennium Pharmaceuticals in Cambridge, MA, in the discovery organization.
Nancy is Chair of the Board of Latigo Bio, a Thousand Oaks–based biotech focused on nonopioid pain medicines. Nancy also serves as a director of the not-for-profit board of PanCAN, the Pancreatic Cancer Action Network. In the past, Nancy has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures.
Nancy has a PhD in Neuroscience from the University of Miami School of Medicine, an MS in Biomedical Engineering, and a BS in Electrical Engineering, both from Drexel University.
Adam Rosenthal PHD
CEO, Founder, and Board Chair
Adam founded Star Therapeutics in 2018 and has served as Chief Executive Officer since its inception. He brings previous operating experience across multiple biotech companies, and broad expertise in company building, fundraising, business development, and strategic planning.
Previously, Adam served as Chief Business Officer at True North Therapeutics, where he raised more than $140M in private financings and contributed to the company’s acquisition by Bioverativ for $825M. His experience also includes serving as Vice President, Head of Corporate Development at iPierian, which was acquired by BMS for $725M, and being a Project Leader at the Boston Consulting Group.
Adam earned BS degrees in Electrical Engineering and Brain and Cognitive Science, and an MEng degree in Electrical Engineering and Computer Science, all at the Massachusetts Institute of Technology, as well as a PhD in Biomedical Engineering at Massachusetts Institute of Technology and Harvard.
CARL GORDON PHD, CFA
Director
Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. He currently serves on the boards of directors of several public and private companies.
Carl received a BA in Chemistry from Harvard College and a PhD in Molecular Biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.
Vish Sridharan MD
Board Observer
Vish Sridharan is an Assistant Portfolio Manager and Research Analyst at Janus Henderson Investors, where he helps manage the firm’s biotech strategy. He was previously in practice at Massachusetts General Hospital. Vish received a Bachelor of Science degree (Hons) in chemistry from the University of North Carolina, graduating Phi Beta Kappa, and an MBA from Harvard Business School. He also earned a doctor of medicine degree from the Harvard-MIT Program in Health Science and Technology, graduating with honors. He is board-certified in Internal Medicine and continues to see hospitalized patients in an ad-hoc capacity.
AMRIT NAGPAL
Director
Amrit is a Partner and Managing Director at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York. Prior to Redmile Group, he worked as an analyst and portfolio manager at Weintraub Capital Management, and before that at Robertson Stephens, a San Francisco–based investment bank.
Amrit holds a BA in Economics from Columbia University and an MBA from UCLA Anderson School of Management.
Matthew Hammond PHD, MBA
Board Observer
Matthew is a Principal on the Investment Team at RA Capital Management. He works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, Emergence Therapeutics, Forge Biologics, and Jnana Therapeutics. He previously served as a Director for DTx Pharma prior to its acquisition by Novartis, and as the CFO of Research Alliance Corp I before its merger with Point Biopharma.
Matthew holds a BS in Environmental Health Science from the University of Georgia and both a PhD in Biomedical Science and an MBA with a concentration in Finance from the University of Connecticut. His graduate research investigated innate immune responses after intracerebral hemorrhage.
Matthew Fust, MBA
Director
Matthew is a board member and advisor to life sciences companies. He serves on the boards of Nasdaq-listed Atara Biotherapeutics, Crinetics Pharmaceuticals, Neumora Therapeutics, and Ultragenyx Pharmaceutical, and on the boards of several venture-backed companies. He also consults with life sciences companies on corporate finance and strategy topics.
Previously, Matthew served as a Chief Financial Officer for biopharmaceutical companies including Onyx Pharmaceuticals, Jazz Pharmaceuticals, and ALZA Corporation, and was a consultant in Andersen Consulting’s healthcare strategy practice.
Matthew holds an undergraduate degree in Accounting from the University of Minnesota and an MBA from the Stanford University Graduate School of Business.
OUR
Investors
